Delivering mRNAs to mouse tissues using the SEND system
Ohtsuka, M.; Imafuku, J.; Hori, S.; Kurosaki, A.; Nakamura, A.; Nakahara, T.; Yahata, T.; Bhat, K.; Papastefan, S.; Nakagawa, S.; Quadros, R. M.; Miura, H.; Gurumurthy, C. B.
Show abstract
mRNAs produced in a cell are almost always translated within the same cell. Some mRNAs are transported to other cells of the organism through processes involving membrane nanotubes or extracellular vesicles. A recent report describes a surprising new phenomenon of encapsulating mRNAs inside virus-like particles (VLPs) to deliver them to other cells in a process that was named SEND (Selective Endogenous eNcapsidation for cellular Delivery). Although the seminal work demonstrates the SEND process in cultured cells, it is unknown whether this phenomenon occurs in vivo. Here, we demonstrate the SEND process in living organisms using specially designed genetically engineered mouse models. Our proof of principle study lays a foundation for the SEND-VLP system to potentially be used as a gene therapy tool to deliver therapeutically important mRNAs to tissues.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Discovery and validation of novel human genomic safe harbor sites for gene and cell therapies 92%
- Optical opening of the blood brain barrier for targeted and ultra-sparse viral infection of cells in the mouse cortex 92%
- Noninvasive focal transgene delivery with viral neuronal tracers in the marmoset monkey 90%
Similar papers in this journal
- Selection of rAAV Vectors that Cross the Human Blood-Brain Barrier 1 and Target the Central Nervous System Using a Transwell Model 94%
- Hypoxia-directed tumor targeting of CRISPR/Cas9 and HSV-TK suicide gene therapy using lipid nanoparticles 94%
- Efficient Gene Transduction in Pigs and Macaques with the Engineered AAV Vector AAV.GT5 for Hemophilia B Gene Therapy 93%
Similar papers in this journal
- Preclinical lentiviral vector-mediated hematopoietic stem and progenitor cell gene therapy corrects Pompe disease-related muscle and neurological manifestations 93%
- A truncated reverse transcriptase enhances prime editing by split AAV vectors 92%
- A Precision Gene Engineered B Cell Medicine Producing Sustained Levels of Active Factor IX for Hemophilia B Therapy 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.